Frequency of Hepatitis C in hospitalized patients with chronic kidney disease

Salman Tahir Shafi1, Muhammad Zaigham Hassan2, Mohammed Saleem3, Roshina Anjum4, Wajid Abdullah5, Tahir Shafi6

ABSTRACT

Background and Objectives: Hepatitis C and chronic kidney disease (CKD) are major global health problems and are highly prevalent in Pakistan. There is limited information on prevalence of hepatitis C in patients with CKD not yet on dialysis. The objective of this study was to determine the frequency of hepatitis C in hospitalized chronic kidney disease patients at a tertiary care center in Pakistan.

Methods: The study design was cross-sectional in nature. Patients between ages of 20-80 years with CKD not previously on renal replacement therapy and who were admitted to nephrology ward at a tertiary care facility were included. Hepatitis C was tested using 3rd generation enzyme linked immunosorbent assay (ELISA). Hepatitis C RNA was tested by polymerase chain reaction (PCR) in patients with positive ELISA.

Results: A total of 180 patients were included in the study. Mean age of patients was 48.7±14.9 years. Of all patients, 105 (58.3%) were males and 75 (41.7%) were females, 152 (84.4%) had hypertension, 113 (62.8%) had diabetes mellitus and 26 (14.9%) had known cardiovascular disease. Mean eGFR of patients was 11.4±9.4 ml/min/1.73 m2. Of all patients with CKD, 49 (27.2%) had hepatitis C test positive by ELISA. Hepatitis C PCR testing was done in 39 patients with hepatitis C ELISA positive status and 29 (74.4%) tested positive. Risk factors and clinical characteristics of patients with and without positive hepatitis C antibody by ELISA were similar.

Conclusion: A significant proportion of hospitalized CKD patients have hepatitis C. Strict universal infection control measures should be implemented in nephrology wards to prevent transmission of hepatitis C infection.

KEY WORDS: Hepatitis C, Chronic Kidney Disease, Frequency.

doi: https://doi.org/10.12669/pjms.331.11553

INTRODUCTION

Both Hepatitis C and chronic kidney disease (CKD) are major global public health problems. It is estimated that worldwide more than 185 million people have hepatitis C. Of these patients, 50-85% develop chronic infection.1 A substantial portion of these patients develops cirrhosis over long term and a subset of these patients develops hepatocellular carcinoma.2 Prevalence of hepatitis C in Pakistani population is 6.8% with up to 25% in rural areas.3 Prevalence of CKD based on health screening camps and community in Pakistan has been found to be around 12.5%–25%.4-6
Hepatitis C in hospitalized patients with CKD

There is a strong and causal relationship between chronic hepatitis C infection and kidney disease especially those of glomerular origin. Several glomerular diseases including mixed cryoglobulinemia, membranous nephropathy, membranoproliferative glomerulonephritis and polyarteritis nodosa are associated with hepatitis C.7

Several epidemiological studies have explored prevalence of hepatitis C in patients on hemodialysis. Prevalence of hepatitis C in hemodialysis patients in Pakistan is 23.7%-56.6%.8-11 However, there is limited local data on prevalence of hepatitis C in patients with CKD not yet on hemodialysis and international studies have shown variable results. Prevalence of hepatitis C antibody has ranged from 1.01% to 20% in patients with CKD in Peru, Spain, Turkey and Italy.1218 Since prevalence of hepatitis C is high in general and hemodialysis population in Pakistan, its prevalence may be different in local CKD patients not yet on hemodialysis compared to international data.

The objective of this study was to determine the frequency of hepatitis C in hospitalized chronic kidney disease patients at a tertiary care center in Pakistan.

METHODS

The study design was cross-sectional in nature. The study was approved by institutional review board. Patients between ages of 20-80 years with CKD not previously on renal replacement therapy (hemodialysis or peritoneal dialysis) and who were admitted to nephrology ward at a tertiary care facility were included. Informed consent was obtained from patients. CKD was defined as estimated GFR (eGFR) of less than <60 ml/min/1.73 m² or persistent proteinuria by urinary dipstick for 3 or more months.19 eGFR was calculated by CKD-EPI formula as follows: GFR = 141 X min(Scr/κ,1) α X max(Scr/κ,1) -1.209 X 0.993^Age X 1.018 [if female], Where Scr is serum creatinine (mg/dL), κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1.20

Sampling technique was non-probability consecutive sampling. Sample size of 171 was calculated with 95% confidence level, 6% margin of error and taking expected percentage of CKD patients with hepatitis C as 20%.

Patient’s history, medical records and laboratory information were reviewed to obtain data on patient’s age, sex, history of hypertension, diabetes mellitus, cardiovascular disease, serum creatinine, eGFR, and urine protein to creatinine ratio. Cardiovascular disease was defined as known prior history of coronary artery disease, cerebrovascular disease or peripheral vascular disease based on history and review of prior medical records. In addition, information was obtained regarding risk factors for hepatitis C including prior history of blood transfusion, IV drug use, prior surgery or whether patient is a known health care professional. Liver function tests were obtained in patients with hepatitis C positive status. Total bilirubin was measured by Jendrassik-Grof method. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) were measured using kinetic method. Hepatitis C was tested using 3rd generation enzyme linked immunosorbent assay (ELISA). Hepatitis C RNA was tested by polymerase chain reaction (PCR) in patients with positive ELISA.

Statistical Analysis: Continuous parametric variables were reported as means ± standard deviation; and categorical variables were expressed as percentages. Patients were divided into two groups based on presence of hepatitis C antibody by ELISA. Categorical variables were compared using the chi-square test, and continuous variables were compared using t-test. All statistical analyses were performed using SPSS 20.0 (Chicago, IL USA). For all tests, p values of <0.05 were considered statistically significant.

RESULTS

A total of 180 patients were included in the study. Mean age of patients was 48.7±14.9 years. Of all patients, 105 (58.3%) were males and 75 (41.7%) were females, 139 (77.2%) were married, 32 (26.7%) were smokers, 31 (17.2%) had dyslipidemia, 152 (84.4%) had hypertension, 113 (62.8%) had diabetes mellitus and 26 (14.9%) had known cardiovascular disease. Mean eGFR of patients was 11.4±9.4 ml/min/1.73 m². Of all patients, 134 (77.5%) had stage V CKD, 27 (15.6%) had stage IV CKD and 9 (5.2%) had stage III CKD.

Of all patients with CKD, 49 (27.2%) had hepatitis C test positive by ELISA. Hepatitis C PCR testing was done in 39 patients with hepatitis C ELISA positive status and 29 (74.4%) tested positive. Liver function tests were done in patients with positive hepatitis C antibody. Mean serum total bilirubin was 0.88±0.9 mg/dL, mean serum direct bilirubin was 0.50±0.70 mg/dL, mean ALT was 39.1±28.6
IU/L, mean AST was 34.7±12.3 IU/L, mean alkaline phosphatase was 240.8±77.7 IU/L. Proportion of patients with elevated ALT (i.e. > 40 IU/L) was 29.4%. Characteristics of patients with and without hepatitis C antibody by ELISA are compared in Table-I.

## Table-I: Comparison of characteristics of patients based on status of hepatitis C antibody by ELISA.

| Characteristics                  | Patients with positive hepatitis C antibody by ELISA (N=49) | Patients with negative hepatitis C antibody by ELISA (N=131) | P value |
|----------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|---------|
| Mean age (years)                 | 48.7±13.8                                                   | 48.7±15.4                                                   | 0.99    |
| Male Sex                         | 61.2%                                                       | 57.3%                                                       | 0.63    |
| Marital status                   | 73.5%                                                       | 78.6%                                                       | 0.16    |
| Hypertension                     | 89.8%                                                       | 83.7%                                                       | 0.21    |
| Diabetes Mellitus                | 75.0%                                                       | 60.2%                                                       | 0.06    |
| Cardiovascular Disease           | 18.4%                                                       | 20.6%                                                       | 0.76    |
| Smokers                          | 30.6%                                                       | 22.8%                                                       | 0.29    |
| Mean duration of CKD (months)    | 9.9±3.9                                                     | 7.4±2.1                                                     | 0.72    |
| H/O of IV drug use prior to hospitalization | 10.2%                                                  | 8.5%                                                       | 0.72    |
| H/O of blood transfusion         | 27.7%                                                       | 26.0%                                                       | 0.83    |
| H/O of prior hospitalization     | 34.7%                                                       | 29.2%                                                       | 0.48    |
| H/O of prior surgery             | 28.6%                                                       | 25.3%                                                       | 0.41    |
| Health care worker               | 8.5%                                                        | 4.7%                                                        | 0.34    |

DISCUSSION

Our study showed that frequency of hepatitis C antibody by ELISA in CKD patients was 27.2%. To our knowledge, this is the largest study of frequency of hepatitis C antibody in CKD patients not yet on hemodialysis in Pakistan.

In an old study in 1994 in Pakistan by Kumar H, frequency of hepatitis C antibody was 6% in 48 patients with CKD. However, this study is old and has very small sample size. International studies have shown variable results. In an Italian study of pre-dialysis CKD patients, incidence of hepatitis C was found to be 6.25% in 320 patients. In another study in Spain, hepatitis C antibody was present in 7.9% of 226 CKD patients with frequency of 13% in patients with creatinine clearance less than 30 ml/min. In a study by Fabrizi et al, hepatitis C antibody was present in 20% of CKD patients. In other studies, hepatitis C antibody was present in 3.9% and 7.0%. Variation in results is likely explained by variation in prevalence of hepatitis C in various geographic regions, different time periods of various studies, variation in methods for detecting hepatitis C antibody and practice of infection control measures in different countries.

Though prevalence of hepatitis C is high in Pakistan, frequency of hepatitis C antibody in CKD patients in our study is significantly higher compared to general population. In various local studies in hospital setting in Pakistan, prevalence of hepatitis C has been found to be 3.3%-30.2% with most studies reporting higher prevalence compared to general population.

Frequency of hepatitis C antibody in hemodialysis patients in Pakistan has been found to be around 23.7%-56.6%. In one study, hepatitis C antibody was present in 19.7% of patients even before start of hemodialysis. This implies, that high frequency of hepatitis C antibody in CKD patients prior to start of hemodialysis may in part contribute to high prevalence of hepatitis C in hemodialysis patients in Pakistan.

Use of hepatitis C antibody by ELISA may result in over-estimation of hepatitis C diagnosis, as some patients may have past infection with hepatitis C. In our study, hepatitis C PCR results were available for in 39 out of 49 patients due to loss of follow up. Hepatitis C PCR was positive in 74% of these patients, which is still significantly high compared to general population. We also couldn’t identify any specific risk factors for hepatitis C in our patient population, which may be due to relatively small sample size. Other studies in CKD population have identified low creatinine clearance, history of blood transfusion, duration of CKD, history of intravenous drug use and elevated ALT levels to be associated with hepatitis C.

Our study results have several implications. First, strict universal infection control measures should be employed in hospital wards where CKD patients are admitted to prevent transmission of infection to other patients and health care workers. In addition, hepatitis C infection has been associated with greater risk of development and progression of CKD. Identification and treatment of hepatitis C in
Hepatitis C in hospitalized patients with CKD

CKD patients may ameliorate progression of CKD, though this has to be verified through randomized controlled trials.

Limitations of the study: Our study has several limitations. This is a single center study in hospitalized CKD patients only with limited sample size. Results may not be applicable to CKD patients seen in out-patient setting. In addition, we couldn’t identify any specific risk factor for hepatitis C infection in our CKD population. Hepatitis C PCR test results were available for majority but not all patients with hepatitis C ELISA antibody.

CONCLUSION

Frequency of hepatitis C ELISA antibody is significantly high in hospitalized CKD patients. Strict universal infection control measures should be implemented in nephrology wards to prevent transmission of hepatitis C infection. Further studies are needed to see whether identification and treatment of hepatitis C in CKD patients will improve mortality or progression to end stage renal disease.

Declaration of interest: None.

REFERENCES

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333-1342. doi: 10.1002/hep.26141.

2. Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology. 2014;59(1):109-120. doi: 10.1002/hep.26639.

3. Umer M, Iqbal M. Hepatitis C virus prevalence and genotype distribution in Pakistan: Comprehensive review of recent data. World J Gastroenterol. 2016;22(4):1684-1700.

4. Imran S, Sheikh A, Saeed Z, Khan SA, Malik AO, Patel J et al. Burden of chronic kidney disease in an urban city of Pakistan, a cross-sectional study. J Pak Med Assoc. 2015;65:366-369.

5. Alam A, Amanullah F, Baig-Ansari N, Lotia-Farrukh I, Khan FS. Prevalence and risk factors of kidney disease in urban Karachi: Baseline findings from a community cohort study. BMC Res Notes. 2014;7:179. doi: 10.1186/1756-0500-7-179.

6. Jessani S, Bux R, Jafar TH. Prevalence, determinants, and management of chronic kidney disease in Karachi, Pakistan - a community based cross-sectional study. BMC Nephrol. 2014;15:90. doi: 10.1186/1471-2369-15-90.

7. Morales JM, Kamar N, Rostaing L. Hepatitis C and renal disease: epidemiology, diagnosis, pathogenesis and therapy. Contrib Nephrol. 2012;176:10-23. doi: 10.1159/000333772.

8. Shafiq F, Akram S, Hashmat N. Prevalence of Hepatitis C in patients with Endstage Renal Disease before and during Hemodialysis. Pak J Gastroenterol. 2002;16(1):17-20.

9. Khokhar N, Alam AY, Naz F, Mahmud SN. Risk factors for Hepatitis C virus infection in patients on long-term hemodialysis. J Coll Physicians Surg Pak. 2005;15(6):326-328.

10. Shafi ST, Haq R, Shafi T. Prevalence and rate of seroconversion of Hepatitis C in hemodialysis patients. Proceeding Shaikh Zayed Postgrad Med Inst. 2003;17(1):19-22.

11. Khan S, Attaullah S, Ali I, Ayaz S, Naseemullah, Khan SN et al. Rising burden of Hepatitis C Virus in hemodialysis patients. Virol J. 2011;8:438. doi: 10.1186/1743-422X-8-438.

12. Kumar H, Naqvi SA, Ahmed A, Hamid S. Hepatitis-C virus antibodies (anti HCV) in haemodialyzed vs non-dialyzed patients. J Pak Med Assoc. 1994;44(2):28-30.

13. Li Cavoli G, Ferrantelli A, Bono L, Tortorici C, Giammarresi C, Zagarri G et al. Incidence of hepatitis C virus infection in patients with chronic kidney disease on conservative therapy. Int J Infect Dis. 2011;15(8):e514-e516.

14. Garcia-Valdecasas J, Bernal C, Garcia F, Cerezo S, UmanaWO, von Albertini B et al. Epidemiology of hepatitis virus infection in patients with renal disease. J Am Soc Nephrol. 1994;5(2):186-192.

15. De Los Rios R, Bussalleu A, Hurtado A, Valdivia J, Huerta Mercado J, Battilana C et al. Prevalence of anti hepatitis C antibodies in patients with chronic renal failure receiving conservative therapy. Rev Gastroenterol Peru. 2006;26(3):265-271.

16. Fabrizi F, Marcelli D, Bacchini G, Guarnori I, Erba G, Locatelli F. Antibodies to hepatitis C virus (HCV) in chronic renal failure (CRF) patients on conservative therapy: prevalence, risk factors and relationship to liver disease. Nephrol Dial Transplant. 1994;9(7):780-784.

17. Lemos LB, Perez RM, Lemos MM, Draibe SA, Silva IS, Silva AE et al. Hepatitis C among predialysis patients: prevalence and characteristics in a large cohort of patients. Nephron Clin Pract. 2008;108(2):c135-c140. doi: 10.1159/000114452.

18. Sit D, Kadiroglu AK, Kayabasi H, Yilmaz ME, Goral V. Seroprevalence of hepatitis B and C viruses in patients with chronic kidney disease on conservative therapy. Int J Infect Dis. 2011;15(8):e514-e516.

19. KDIGO. Chapter 1: Definition and classification of CKD. Kidney Int Suppl. 2013;3:19.

20. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612.

21. Park H, Adeyemi A, Henry L, Stepanova M, Younossi Z. A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection. J Viral Hepat. 2015;22(11):897-905. doi: 10.1111/jvh.12413.

Authors Contribution:

STS: Study design, data analysis, manuscript writing
MZH: Data collection and interpretation
MS: Data collection and interpretation
RA: Data collection and analysis
WA: Data collection and interpretation
TS: Manuscript revision

All authors have reviewed and approved the manuscript.